Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1

被引:440
作者
Gostissa, M
Hengstermann, A
Fogal, V
Sandy, P
Schwarz, SE
Scheffner, M
Del Sal, G
机构
[1] Consorzio Interuniv Biotecnol, Lab Nazl, I-34012 Trieste, Italy
[2] Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, I-34100 Trieste, Italy
[3] Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany
关键词
p53; regulation; SUMO-1; transactivation; Ubc9;
D O I
10.1093/emboj/18.22.6462
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
The growth-suppressive properties of p53 are trolled by posttranslational modifications and by regulation of its turnover rate. Here we show that p53 can be modified in vitro and in vivo by conjugation to the small ubiquitin-like protein SUMO-1. A lysine residue at amino acid position 386 of p53 is required for this previously undescribed modification, strongly suggesting that this lysine residue serves as the major attachment site for SUMO-1, Unlike ubiquitin, attachment of SUMO-1 does not appear to target proteins for rapid degradation but rather, has been proposed to change the ability of the modified protein to interact with other cellular proteins. Accordingly, we provide evidence that conjugation of SUMO-1 to wild-type p53 results in an increased transactivation ability of p53. We suggest that posttranslational modification of p53 by SUMO-1 conjugation provides a novel mechanism to regulate p53 activity.
引用
收藏
页码:6462 / 6471
页数:10
相关论文
共 44 条
[1]
The NF-kappa B and I kappa B proteins: New discoveries and insights [J].
Baldwin, AS .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :649-683
[2]
Boddy MN, 1996, ONCOGENE, V13, P971
[3]
Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins [J].
Chelbi-Alix, MK ;
de Thé, H .
ONCOGENE, 1999, 18 (04) :935-941
[4]
SUMO-1 modification of IκBα inhibits NF-κB activation [J].
Desterro, JMP ;
Rodriguez, MS ;
Hay, RT .
MOLECULAR CELL, 1998, 2 (02) :233-239
[5]
Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1 [J].
Desterro, JMP ;
Rodriguez, MS ;
Kemp, GD ;
Hay, RT .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (15) :10618-10624
[6]
WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION [J].
ELDEIRY, WS ;
TOKINO, T ;
VELCULESCU, VE ;
LEVY, DB ;
PARSONS, R ;
TRENT, JM ;
LIN, D ;
MERCER, WE ;
KINZLER, KW ;
VOGELSTEIN, B .
CELL, 1993, 75 (04) :817-825
[7]
The complexity of p53 modulation: emerging patterns from divergent signals [J].
Giaccia, AJ ;
Kastan, MB .
GENES & DEVELOPMENT, 1998, 12 (19) :2973-2983
[8]
Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain [J].
Gu, W ;
Roeder, RG .
CELL, 1997, 90 (04) :595-606
[9]
CDI1, A HUMAN G1-PHASE AND S-PHASE PROTEIN PHOSPHATASE THAT ASSOCIATES WITH CDK2 [J].
GYURIS, J ;
GOLEMIS, E ;
CHERTKOV, H ;
BRENT, R .
CELL, 1993, 75 (04) :791-803
[10]
Mdm2 promotes the rapid degradation of p53 [J].
Haupt, Y ;
Maya, R ;
Kazaz, A ;
Oren, M .
NATURE, 1997, 387 (6630) :296-299